Applied TherapeuticsAPLT
About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Employees: 35
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
72% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 25
47% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $969K
0.74% more ownership
Funds ownership: 98.15% [Q3] → 98.89% (+0.74%) [Q4]
6% less funds holding
Funds holding: 125 [Q3] → 118 (-7) [Q4]
13% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 45
50% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]
90% less capital invested
Capital invested by funds: $961M [Q3] → $98.5M (-$862M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for APLT.
Financial journalist opinion









